Jazz Pins Sativex US Hopes On Two Advanced Studies After First MS Spasticity Trial Flunks
Executive Summary
The Irish firm’s cannabis-derived nabiximols spray missed the primary endpoint in a late-stage multiple sclerosis spasticity trial, but it is unfazed as hopes remain for two ongoing spasticity studies.
You may also be interested in...
Jazz Trumpets 2025 Strategy With Neurology, Oncology Focus
The company laid out plans at J.P. Morgan to reach revenues of $5bn by 2025, focusing on already marketed products and its pipeline plans.
Jazz Wades Into Cannabinoid Weeds With $7.2bn GW Buy
Priced at a 50% premium to GW’s value, the deal will reduce the percentage of Jazz’s drug sales coming from Xyrem, provide double-digit revenue growth and expand the R&D pipeline to 19 programs.